Sponsored Links
| Transave Completes Successful Phase II Clinical Program For ARIKACE In The Treatment Of Pseudomonas Lung Infections |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Transave Inc., reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. Read more: Pharma Industry / Biotech Industry News From Medical News Today
|